GlassScriptPhysician profile
Spiros Mitsopoulos
NPI 1720034390
$1,964.44
in general payments reported to CMS, 2019-2025
16 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $248 · 2021: $319 · 2022: $255 · 2023: $329 · 2024: $263 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $644.70 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $393.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $179.88 | 2020-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $156.65 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.60 | 2023-2025 | Xifaxan, Trulance |
| Abbvie INC. | $95.55 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.84 | 2019-2021 | |
| Astellas Pharma US INC | $74.91 | 2023-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $54.09 | 2019-2022 | |
| Eisai INC. | $41.88 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $32.94 | 2020-2021 | |
| Glaxosmithkline, LLC. | $29.39 | 2023-2025 | Trelegy Ellipta |
| Abbott Laboratories | $24.53 | 2023 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $21.97 | 2019 | |
| Allergan, INC. | $12.70 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spiros Mitsopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.